Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion

Summary

Continuous-infusion of piperacillin/tazobactam over 4 hrs instead of 30-minute intermittent dosage regimen has shown observable outcomes. Our objective is to assess whether continuous infusion of piperacillin/tazobactam is superior in terms of efficacy, safety and cost to the intermittent regimen to treat suspected or proved infections due to gram negative bacteria. The setting is Critical Care Medicine Department at Cairo University Hospitals. Methods A prospective randomized comparative study.

Timeline

Start

2018-07-27

Primary completion

2020-01-26

Completion

2020-01-26

Drugs

Indications